Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Thyroid Neoplasms 9Hypothyroidism 7Thyroid Diseases 1Thyroid Cancer, Papillary 1Sarcoma, Alveolar Soft Part 1Recurrence 1Postoperative Complications 1Polycystic Ovary Syndrome 1Neoplasms 1Laryngeal Neoplasms 1Infertility, Female 1Head and Neck Neoplasms 1Goiter 1Fatigue 1Depression 1Brain Neoplasms 1Anxiety Disorders 1Advanced Differentiated Thyroid Gland Carcinoma 1

Interventions

Cyclophosphamide 153Dexamethasone 141Rituximab 85fludarabine 79Lenalidomide 72Cytarabine 70Bortezomib 64fludarabine phosphate 63Gemcitabine 62venetoclax 54Etoposide 53pomalidomide 52pembrolizumab 52Paclitaxel 48Cisplatin 48Carboplatin 48Peripheral Blood Stem Cell Transplantation 47Filgrastim 40Radiotherapy 39Busulfan 37Calcium Dobesilate 36Methotrexate 34Melphalan 34Bevacizumab 33carfilzomib 32Cyclosporine 32Azacitidine 32Mycophenolic Acid 30Vincristine 29Bendamustine Hydrochloride 29

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recurrence × Thyroxine × Clear all
NCT06087068 2023-10-17

Thyroxine Replacement Therapy After Lobectomy for Low-risk Papillary Thyroid Carcinoma

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Recruiting
140 enrolled
Head & Neck

Recurrence, Thyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡